BioSpace News Archive

Today, Johnson & Johnson Innovation – JLABS (JLABS) and Janssen Research & Development, LLC, in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services

U.S. News & World Report, the global authority in healthcare rankings, released the 2020 Best Insurance Companies for Medicare Advantage and Prescription Drug Plans.

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat serious inflammatory diseases, today announced that the Company will present at the 2019 BIO Investor Forum being held October 22-23, 2019 in San Francisco, CA

Tactical Medical Solutions, LLC (“TacMed”), a leading innovator and manufacturer of proprietary pre-hospital medical components and technology for tactical and civilian applications, and Guardian Capital Partners, announce the acquisition of TraumaFX Solutions, Inc. (“TFX”).

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, will showcase innovative RNA sequencing applications using microfluidics technology at the American Society of Human Genetics (ASHG) annual meeting in Houston, Texas, from October 15 to 19. “As the demand for RNA NGS sequencing continues to rise, many genomics laboratories have found i

ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it intends to offer and sell $50,000,000 of its ordinary shares in an underwritten public offering.

The investment shall be used to scale up and accelerate the commercialisation activities of CURIOX globally.

Another rugged version of nScrypt’s bioprinter was launched to the International Space Station in July 2019, for bioprinting human heart tissue in microgravity.

Sorrento Therapeutics, Inc. announced today that a Los Angeles Superior Court judge has rejected Patrick Soon-Shiong’s attempt to allow him and his company, NantPharma, to avoid the billion-dollar fraud and breach of contract claims that Sorrento filed against them earlier this year.

ProQR Therapeutics N.V. announced the pricing of its previously announced underwritten public offering of 9,090,909 ordinary shares at a price to the public of $5.50 per share.